PT92013A - Processo para a preparacao de uma nova familia de anticorpos modificados com afinidade elevada para o tratamento de cancro - Google Patents

Processo para a preparacao de uma nova familia de anticorpos modificados com afinidade elevada para o tratamento de cancro

Info

Publication number
PT92013A
PT92013A PT92013A PT9201389A PT92013A PT 92013 A PT92013 A PT 92013A PT 92013 A PT92013 A PT 92013A PT 9201389 A PT9201389 A PT 9201389A PT 92013 A PT92013 A PT 92013A
Authority
PT
Portugal
Prior art keywords
preparing
cancer treatment
modified antibodies
new family
high release
Prior art date
Application number
PT92013A
Other languages
English (en)
Other versions
PT92013B (pt
Inventor
Peter Mezes
Brian Gourlie
Mark Rixon
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of PT92013A publication Critical patent/PT92013A/pt
Publication of PT92013B publication Critical patent/PT92013B/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT92013A 1988-10-19 1989-10-17 Processo para a preparacao de uma nova familia de anticorpos modificados com afinidade elevada para o tratamento de cancro PT92013B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25994388A 1988-10-19 1988-10-19

Publications (2)

Publication Number Publication Date
PT92013A true PT92013A (pt) 1990-04-30
PT92013B PT92013B (pt) 1995-07-06

Family

ID=22987104

Family Applications (1)

Application Number Title Priority Date Filing Date
PT92013A PT92013B (pt) 1988-10-19 1989-10-17 Processo para a preparacao de uma nova familia de anticorpos modificados com afinidade elevada para o tratamento de cancro

Country Status (21)

Country Link
EP (2) EP0397821A4 (pt)
JP (1) JP2935520B2 (pt)
KR (1) KR0161525B1 (pt)
AR (1) AR242434A1 (pt)
AT (1) ATE111519T1 (pt)
AU (2) AU4429989A (pt)
BR (1) BR8907126A (pt)
CA (1) CA2000913C (pt)
DE (1) DE68918217T2 (pt)
DK (1) DK173089B1 (pt)
ES (1) ES2059670T3 (pt)
FI (1) FI103181B1 (pt)
HK (1) HK162795A (pt)
HU (1) HU218093B (pt)
IE (1) IE64966B1 (pt)
IL (1) IL92037A (pt)
NO (1) NO301075B1 (pt)
NZ (1) NZ231012A (pt)
PT (1) PT92013B (pt)
WO (1) WO1990004410A1 (pt)
ZA (1) ZA897858B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5976531A (en) * 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
US6495137B1 (en) 1990-04-19 2002-12-17 The Dow Chemical Company Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0523949B1 (en) * 1991-07-15 2003-06-25 The Wellcome Foundation Limited Production of antibodies
US6025165A (en) * 1991-11-25 2000-02-15 Enzon, Inc. Methods for producing multivalent antigen-binding proteins
AU696627B2 (en) * 1991-12-13 1998-09-17 Dow Chemical Company, The Composite antibodies of human subgroup IV light chain capable of binding to TAG-72
EP0618969B1 (en) * 1991-12-13 2003-06-25 The Dow Chemical Company Composite antibodies of human subgroup iv light chain capable of binding to tag-72
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
JP3312357B2 (ja) 1992-12-11 2002-08-05 ザ ダウ ケミカル カンパニー 多価の一本鎖抗体
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
IL138021A0 (en) * 1998-02-25 2001-10-31 Dow Chemical Co High affinity humanized anti-tag-72 monoclonal antibodies
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
EP1532162B1 (en) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US73685A (en) * 1868-01-21 Improvement in ploughs
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
FR2788040B1 (fr) * 1998-12-31 2001-03-23 Airsec Sa Distributeur d'objets

Also Published As

Publication number Publication date
KR900701302A (ko) 1990-12-01
FI103181B (fi) 1999-05-14
JPH03502889A (ja) 1991-07-04
ZA897858B (en) 1991-06-26
DE68918217D1 (de) 1994-10-20
EP0365997B1 (en) 1994-09-14
HUT56878A (en) 1991-10-28
BR8907126A (pt) 1991-02-13
FI903056A0 (fi) 1990-06-18
CA2000913A1 (en) 1990-04-19
EP0397821A4 (en) 1992-03-18
IL92037A0 (en) 1990-07-12
HU896255D0 (en) 1991-09-30
AU4429989A (en) 1990-05-14
IE64966B1 (en) 1995-09-20
ATE111519T1 (de) 1994-09-15
CA2000913C (en) 1999-02-16
HU218093B (hu) 2000-05-28
WO1990004410A1 (en) 1990-05-03
NO301075B1 (no) 1997-09-08
EP0365997A2 (en) 1990-05-02
EP0397821A1 (en) 1990-11-22
HK162795A (en) 1995-10-27
PT92013B (pt) 1995-07-06
ES2059670T3 (es) 1994-11-16
NO902696D0 (no) 1990-06-18
DK149990A (da) 1990-08-17
JP2935520B2 (ja) 1999-08-16
EP0365997A3 (en) 1992-03-04
DE68918217T2 (de) 1995-02-09
DK173089B1 (da) 2000-01-10
IE893347L (en) 1990-04-19
NO902696L (no) 1990-08-16
NZ231012A (en) 1993-02-25
AU4354089A (en) 1990-04-26
KR0161525B1 (ko) 1998-12-01
DK149990D0 (da) 1990-06-19
FI103181B1 (fi) 1999-05-14
AU633026B2 (en) 1993-01-21
IL92037A (en) 1998-03-10
AR242434A1 (es) 1993-03-31

Similar Documents

Publication Publication Date Title
PT92013A (pt) Processo para a preparacao de uma nova familia de anticorpos modificados com afinidade elevada para o tratamento de cancro
PT88200A (pt) Processo para a preparacao de uma composicao para o tratamento da pele
PT93452A (pt) Processo para a preparacao de uma pastilha de colestiramina
PT91075A (pt) Processo para a preparacao de imunoconjungados de gelonina com anticorpos especificos de tumor apropriados para o diagnostico e a terapeutica do cancro
PT90119A (pt) Processo para a preparacao de um adocante
BR8901395A (pt) Processo para preparacao de revestimentos fotocurados
BR8702527A (pt) Processo para a preparacao de uma triazol-sulfonamida
PT90293A (pt) Processo para a preparacao de macrolidos
PT91895A (pt) Processo para a preparacao de 9h-purinas substituidas
BR8907013A (pt) Processo para preparacao de uma dimetiltetralina
BR8903484A (pt) Processo e meios para a fabricacao de fechos de correr
PT92694A (pt) Processo para a preparacao de folhas de gelatina
PT90435A (pt) Processo aperfeicoado para a preparacao de uma cetimina
BR8906327A (pt) Processo para a preparacao de organoclorossilanos
BR8902665A (pt) Processo para deslignificacao de material lignocelulosico
PT92638A (pt) Processo para a preparacao de poliazamacrociclos mono-n-alquilados
PT92365A (pt) Processo para a preparacao de (s)-alfa-etil-2-oxo-1-pirrolidinoacetamida
BR8806959A (pt) Composto e processo para a preparacao do mesmo
PT90323A (pt) Processo para a preparacao de anticorpos monoclonais
BR8803678A (pt) Processo para a preparacao de polieteramidas
PT90176A (pt) Processo para a preparacao de um agente de tratamento de gado equideo
BR8903367A (pt) Processo para a preparacao de organoclorossilanos
PT91929A (pt) Processo para a preparacao de pro-uroquinase humana
BR8902030A (pt) Processo para a preparacao de n-fosfonometilglicina
PT89954B (pt) Processo para a preparacao de pirroloquinolina-e pirrolofenotiazina-carboxamidas e de compostos afins

Legal Events

Date Code Title Description
MM3A Annulment or lapse

Effective date: 20050808